Durhane Wong-Rieger – VJRegenMed

Improving patient access to advanced therapies: are we ready for them?

admin_vjr_user — Mon, 05 Jul 2021 13:47:09 +0000

Durhane Wong-Rieger, PhD, Rare Disease International, Toronto, ON, calls for the field of cell and gene therapies and healthcare systems to work towards improving patient access to therapies. The costs associated with novel therapies and the lack of established payment systems, as well as a lack of adequate infrastructure for the delivery of therapies, remain key obstacles for many patients, which will only be exacerbated as therapies for more common indications such as cardiovascular disease become approved in the future. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

Building partnerships between patients and industry

admin_vjr_user — Fri, 30 Apr 2021 10:09:57 +0000

Durhane Wong-Rieger, PhD, Rare Disease International, Toronto, ON, discusses the need for increased engagement between patients and developers of novel cell and gene therapy products, as well as some of the key challenges associated with the integration of patients into the development process. She also highlights the importance of improving patient education on a range of aspects across the field of advanced therapies, including what diseases can be targeted using different technologies, the drug development process, as well as treatment limitations. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

Educating patients in cell and gene therapies

admin_vjr_user — Fri, 30 Apr 2021 10:09:57 +0000

Durhane Wong-Rieger, PhD, Rare Disease International, Toronto, ON, discusses increasing patient involvement in the advanced therapies sector. While the field holds great promise, the fact that the development and regulatory approval of novel therapies can take many years has led to impatience and confusion within the patient community. Dr Wong-Rieger highlights the importance of improving patient education on the different types of gene therapy and calls for greater patient involvement in the development process. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.